Abel U, Kiessig S T
Tumorzentrum Heidelberg/Mannheim, Deutschland.
Infusionsther Transfusionsmed. 1995 Jun;22(3):175-85.
The strategies for combining two screening tests for HIV infections in blood or plasma donors are formulated in biometric terms and analyzed with respect to their value, i.e. their validity, cost and effectiveness.
Biometrical modeling using assumptions on the validity of the single tests, the conditional correlations between them, as well as on the cost of testing and the consequences of false-negative or false-positive test results.
If the test combination is defined as positive whenever at least one of the single tests is positive, then this rule (the 'believe the positive' rule, BTP), due to its lower specificity, has extremely low positive predictive values. In case of high prevalence rates of the infection (e.g. 1:1,000), the BTP rule leads to lower total cost than single testing, unless the latter has very high sensitivity (e.g. 99%). For smaller prevalence rates (< 1:50,000), which are more typical of the selected group of blood or plasma donors, combination testing is of little value because the extra cost of detecting one additional infection (compared with single testing) may reach several 100 million DM.
The cost for detecting additional cases of HIV infection by using combination instead of single testing in HIV screening is so high that this decision requires a public consensus.
从生物统计学角度制定在血液或血浆捐献者中联合两种HIV感染筛查试验的策略,并就其价值,即有效性、成本和效果进行分析。
采用关于单项检测的有效性、它们之间的条件相关性以及检测成本和假阴性或假阳性检测结果后果的假设进行生物统计学建模。
如果将至少一项单项检测呈阳性时的检测组合定义为阳性,那么这条规则(“相信阳性”规则,BTP)由于其较低的特异性,具有极低的阳性预测值。在感染患病率较高(如1:1000)的情况下,BTP规则导致的总成本低于单项检测,除非后者具有非常高的灵敏度(如99%)。对于较低的患病率(<1:50000),这在选定的血液或血浆捐献者群体中更为典型,联合检测几乎没有价值,因为检测出一例额外感染的额外成本(与单项检测相比)可能达到数亿德国马克。
在HIV筛查中使用联合检测而非单项检测来发现额外的HIV感染病例,成本如此之高,以至于这一决策需要公众达成共识。